

In the Specification:

Please amend the paragraph beginning at page 2, line 11 and ending at page 2, line 20 of the specification as follows:

--The hybridoma cell line produces an antibody that specifically binds to amino acid residues 8 to 17 of the rat vascular smooth muscle AT1 receptor, which sequence is also found in the AT1 receptor of human and bovine cells. The epitope sequence is as follows:

EDGIKRIQDD (SEQ ID NO:2)

Or, alternatively expressed as,

NH₂-Glu-Asp-Gly-Ile-Lys-Arg-Ile-Gln-Asp-Asp-COOH--

Please amend the paragraph beginning at page 3, line 1 and ending at page 3, line 7 of the specification as follows:

--According to a first aspect of the invention, there is provided the use of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence

MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1)

or a fragment thereof, in the preparation of a medicament for the treatment of cancer.--

Please amend the paragraph beginning at page 5, line 7 and ending at page 5, line 18 of the specification as follows:

--As stated above, an active subfragment of the specified sequence may be used as defined. Active

subfragments may consist of or include pentapeptides, including one or more of:

TEDGI (SEQ ID NO:3)

EDGIK (SEQ ID NO:4)

DGIKR (SEQ ID NO:5)

GIKRI (SEQ ID NO:6)

IKRIQ (SEQ ID NO:7)

KRIQD (SEQ ID NO:8)

RIQDD (SEQ ID NO:9)

IQDDC (SEQ ID NO:10)--

Please amend the paragraph beginning at page 5, line 20 and ending at page 5, line 31 of the specification as follows:

--Active subfragments may also consist of or include hexapeptides, including one or more of:

STEDGI (SEQ ID NO:11)

TEDGIK (SEQ ID NO:12)

EDGIKR (SEQ ID NO:13)

DGIKRI (SEQ ID NO:14)

GIKRIQ (SEQ ID NO:15)

IKRIQD (SEQ ID NO:16)

KRIQDD (SEQ ID NO:17)

RIQDDC (SEQ ID NO:18)

IQDDCP (SEQ ID NO:19)--

Please amend the paragraph beginning at page 6, line 1 and ending at page 6, line 13 of the specification as follows:

--Active subfragments may alternatively consist of or include heptapeptides, including one or more

of:

SSTEDGI (SEQ ID NO:20)

STEDGIK (SEQ ID NO:21)

TEDGIKR (SEQ ID NO:22)

EDGIKRI (SEQ ID NO:23)

DGIKRIQ (SEQ ID NO:24)

GIKRIQD (SEQ ID NO:25)

IKRIQDD (SEQ ID NO:26)

KRIQDDC (SEQ ID NO:27)

RIQDDCP (SEQ ID NO:28)

IQDDCPK (SEQ ID NO:29)--

Please amend the paragraph beginning at page 6, line 15 and ending at page 6, line 27 of the specification as follows:

--Further, active subfragments may consist of or include octapeptides, including:

NSSTEDGI (SEQ ID NO:30)

SSTEDGIK (SEQ ID NO:31)

STEDGIKR (SEQ ID NO:32)

TEDGIKRI (SEQ ID NO:33)

EDGIKRIQ (SEQ ID NO:34)

DGIKRIQD (SEQ ID NO:35)

GIKRIQDD (SEQ ID NO:36)

IKRIQDDC (SEQ ID NO:37)

KRIQDDCP (SEQ ID NO:38)

RIQDDCPK (SEQ ID NO:39)

IQDDCPKA (SEQ ID NO:40)--

Please amend the paragraph beginning at page 6, line 29 and ending at page 7, line 10 of the specification as follows:

--Further, active subfragments may consist of or include nonapeptides, including:

LNSSTEDGI (SEQ ID NO:41)

NSSTEDGIK (SEQ ID NO:42)

SSTEDGIKR (SEQ ID NO:43)

STEDGIKRI (SEQ ID NO:44)

TEDGIKRIQ (SEQ ID NO:45)

EDGIKRIQD (SEQ ID NO:46)

DGIKRIQDD (SEQ ID NO:47)

GIKRIQDDC (SEQ ID NO:48)

IKRIQDDCP (SEQ ID NO:49)

KRIQDDCPK (SEQ ID NO:50)

RIQDDCPKA (SEQ ID NO:51)

IQDDCPKAG (SEQ ID NO:52)--

Please amend the paragraph beginning at page 7, line 12 and ending at page 7, line 26 of the specification as follows:

--Further, active subfragments may consist of or include decapeptides, including:

ILNSSTEDGI (SEQ ID NO:53)

LNSSTEDGIK (SEQ ID NO:54)

NSSTEDGIKR (SEQ ID NO:55)

SSTEDGIKRI (SEQ ID NO:56)

STEDGIKRIQ (SEQ ID NO:57)

TEDGIKRIQD (SEQ ID NO:58)

EDGIKRIQDD (SEQ ID NO:59)

DOCKET NO.: 133088.00301(P33791US)

PATENT

DGIKRIQDDC (SEQ ID NO:60)

GIKRIQDDCP (SEQ ID NO:61)

IKRIQDDCPK (SEQ ID NO:62)

KRIQDDCPKA (SEQ ID NO:63)

RIQDDCPKAG (SEQ ID NO:64)

IQDDCPKAGR (SEQ ID NO:65)—